


A Diabetic patient with ACS undergoing PCI

Marco Ferlini, MD, FESC

Fondazione IRCCS Policlinico San Matteo, Pavia

Case

- Male, 63 years old
- Risk Factors for CAD: hypertension, hypercholesterolemia, T2DM
- History of PAD
- March 2017: inferior ST elevation MI and primary PCI on CFX in 3 vessel CAD
- Discharged 5 days later: Aspirin, Ticagrelor 90 mg bid, BB, High dose statin, ARB, metformin
- EF > 60%




- **June 2017**
- **NSTEMI: chest pain, raised Troponin, no ECG changes**
- **Coronary angio < 24 hours**
- **Blood samples: cLDL 84 mg/dl**
- **Ongoing Medical therapy: Aspirin, Ticagrelor 90 mg bid, BB, High dose statin plus ezetimibe, ARB, metformin**



- **June 2017**
- **NSTEMI**
- **Coronary angio: CFX ok and PCI on LAD (before FFR evaluation) and on distal RCA**
- **Discharged 4 days later: Aspirin, Ticagrelor 90 mg bid, BB, High dose statin plus ezetimibe, ARB, metformin**
- **PCK9 Inh????**
- **EF > 60%**



- 18 days later
- Onset of typical chest pain
- Directly access to our ER
- Troponin raised at first evaluation
- cLDL 78 mg/dl; HbA1c 7.6%
- **GRACE SCORE 106**
- **CRUSADE BLEED 31**





Which antithrombotic therapy?

- **Fondaparinux**
- **Enoxaparin**
- **UHF**
- **Upstream Gpl**
- **Switch to prasugrel after PCI**

July 2017



OCT of the RCA



PCI ON RCA: WHICH Medical Therapy at discharge?

- **Aspirin**
- **Ticagrelor**
- **BB and ARB**
- **High dose statin plus ezetimibe**
- **Insulin**
- **Adding PCSk9 inhibitors?**
- **More?**

Case Conclusion

- **Despite the improvement of devices and antithrombotic therapy, frequent flyer with ACS remain a challenge**
- **T2DM is one of the major risk factors associated with CAD development**
- **In these particular settings aggressive medical therapy appears as mandatory**